Matt Abernethy

Chief Financial Officer, Neurocrine Biosciences.

Companies

Fate TherapeuticsBoard member May 30, 2025 to now¹
Neurocrine BiosciencesChief financial officer Dec 5, 2017 to now²

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARFate Therapeutics, Board member
2
SEC EDGARNeurocrine Biosciences, Chief financial officer